Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Automation
IT & Software
Return to: PBR Home | Automation | IT & Software

IT & Software

Minerva licenses Sendai Virus technology for stem cell generation Minerva Biotechnologies and ID Pharma (formerly DNAVEC) announced that they have signed an agreement granting Minerva worldwide rights to use and commercialize their non-integrating Sendai virus vectors, together with Minerva’s proprietary technology, for generating Induced Pluripotent Stem (iPS) cells.
Automation > IT & Software > News
Allied-Bristol Life Sciences licenses Yale University's platform technology and lead molecules By PBR Staff Writer
Allied-Bristol Life Sciences (ABLS) has entered into a worldwide licensing agreement with Yale University for a proprietary platform technology and associated lead molecules to further developed new treatments for diseases such as prostate cancer.
Automation > IT & Software > News Immatics, Anderson launch Immatics US to develop multiple T-cell and TCR-based adoptive cellular therapies Immatics Biotechnologies (Immatics) and The University of Texas MD Anderson Cancer Center announced the launch of Immatics US, a new company aiming at becoming a global leader in adoptive cellular therapies (ACT) for the treatment of a range of tumor types.
Automation > IT & Software > News
See more IT & Software news

Latest IT & Software News and Insight

View all IT & Software news or find news targeted to your interests
FDA clears IND application of Biohaven's lead drug candidate BHV-0223
By PBR Staff Writer
The US Food and Drug Administration (FDA) has completed its review of Biohaven Pharmaceutical's investigational new drug (IND) application for BHV-0223 which will see the start of initial clinical studies in humans.
Automation > IT & Software > News
DrugDev centralizes new SaaS solutions development for clinical research
DrugDev is putting out a call to SaaS developers in the Boston area to join the team behind the award-winning, cloud-based software platform that enables clinical trial sponsors, CROs and sites to do more clinical trials together.
Automation > IT & Software > News
Cellectar introduces PDC platform for targeted delivery of chemotherapeutics
By PBR Staff Writer
Cellectar Biosciences (CLRB) has introduced its phospholipid ether-drug conjugate (PDC) platform for expanding the use of its small-molecule cancer targeting and delivery technology for targeted delivery of chemotherapeutics.
Automation > IT & Software > News
Seres secures FDA orphan drug status for SER-109 to prevent recurrent CDI in adults
By PBR Staff Writer
Seres Therapeutics has received orphan drug designation from the US Food and Drug Administration (FDA) for its oral therapeutic, SER-109, being evaluated in a Phase II clinical trial for the prevention of recurrent Clostridium difficile infection (CDI) in adults.
Automation > IT & Software > News
EnGeneIC begins Phase I tailored-EDV clinical trial in solid tumors
By PBR Staff Writer
Australian biopharmaceutical firm EnGeneIC has dosed the first patient in its Phase I Tailored-EDV clinical trial, which is being conducted at the Northern Cancer Institute in Sydney.
Automation > IT & Software > News
Insys's NDA for Dronabinol oral solution accepted for filing by US FDA
By PBR Staff Writer
The US Food and Drug Administration (FDA) has accepted for filing Insys Therapeutics' new drug application (NDA) for its Dronabinol Oral Solution, an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a synthetic version of tetrahydrocannabinol (THC).
Automation > IT & Software > News
Genmab ties up with Novo Nordisk for DuoBody technology
By PBR Staff Writer
Genmab has inked a pact to allow Novo Nordisk to use commercial licenses for DuoBody technology platform to create and develop bispecific antibody candidates for two therapeutic programs.
Automation > IT & Software > News
Boehringer to use Circuit optogenetics technology to develop new obesity drugs
By PBR Staff Writer
Boehringer Ingelheim has entered into a second collaboration with US-based Circuit Therapeutics to use its optogenetics technology platform for the discovery and development of new medicines to treat obesity and associated diseases.
Automation > IT & Software > News
Poseida to use Janssen Centyrin technology to develop CAR therapies
Poseida Therapeutics (Poseida), a private biotechnology company spun out of Transposagen Biopharmaceuticals (Transposagen), and headquartered in San Diego, CA, announced they have entered into a worldwide License Agreement with Janssen Biotech (Janssen) to research, develop, manufacture and commercialize licensed products using Janssen Centyrin technology.
Automation > IT & Software > News
iCardiac acquires nSpire Health's clinical trials division
iCardiac Technologies, a global provider of cardiac safety assessment services to the pharmaceutical industry, announced today that it has added leading respiratory and ePRO services to its suite of offerings through the acquisition of the clinical trials division of nSpire Health.
Automation > IT & Software > News
View all IT & Software news or find news targeted to your interests